Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival without bronchopulmonary dysplasia in extremely preterm infants: an external, population-based validation, comparison and optimisation study of recent prediction models at baseline.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Regulations for international non-proprietary name prescribing and substitution, relevant for cross-border ePrescribing and eDispensation services in the European Union.

European journal of public health·2025
Same author

Prophylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm.

European journal of pediatrics·2025
Same author

Efficacy and safety of pitolisant in residual excessive daytime sleepiness for patients with obstructive sleep apnea adhering to continuous positive airway pressure therapy in the HAROSA studies: An individual patient meta-analytical approach.

Sleep medicine·2025
Same author

Building a Foundation for High-Quality Health Data: Multihospital Case Study in Belgium.

JMIR medical informatics·2024
Same author

Safety comparison of single-donor and pooled fecal microbiota transfer product preparation in ulcerative colitis: systematic review and meta-analysis.

BMC gastroenterology·2024
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

Naftidrofuryl for intermittent claudication.

Tine L M de Backer1, Robert Vander Stichele, Philippe Lehert

  • 1Heart Center, Ghent University Hospital, Ghent, Belgium. tine.debacker@ugent.be

The Cochrane Database of Systematic Reviews
|December 14, 2012
PubMed
Summary
This summary is machine-generated.

Oral naftidrofuryl significantly improves pain-free walking distance in intermittent claudication patients. This meta-analysis of individual patient data confirms its moderate, clinically meaningful benefit over placebo.

More Related Videos

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Related Experiment Videos

Last Updated: May 16, 2026

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Area of Science:

  • Vascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Intermittent claudication (IC) management primarily involves lifestyle changes and cardiovascular prevention.
  • The efficacy of vasoactive agents (ATC CO4A) for symptomatic IC treatment remains debated.
  • Oral naftidrofuryl (ATC CO4 21) is a vasoactive agent used for IC.

Purpose of the Study:

  • To conduct a meta-analysis of individual patient data (IPD) to evaluate oral naftidrofuryl's efficacy and safety.
  • To compare the effect of oral naftidrofuryl versus placebo on pain-free walking distance (PFWD) in IC patients.

Main Methods:

  • Systematic search of relevant databases and trial registers for randomized controlled trials (RCTs).
  • Inclusion of RCTs with low to moderate risk of bias and available IPD.
  • Analysis of IPD using intention-to-treat (ITT) principles, multilevel and random-effect models to assess PFWD improvement and responder rates.

Main Results:

  • Seven studies with 1083 patients (main analysis) were included.
  • Oral naftidrofuryl showed a statistically significant improvement in PFWD compared to placebo (ratio of relative improvement: 1.37; P < 0.001).
  • The absolute difference in responder rate (≥50% PFWD improvement) was 22.3%, with a number needed to treat of 4.5.

Conclusions:

  • Oral naftidrofuryl demonstrates a statistically significant and clinically meaningful, though moderate, improvement in walking distance for IC patients.
  • The findings support the use of naftidrofuryl for symptomatic relief in IC.
  • Enhanced access to IPD from RCTs is crucial for robust meta-analyses, and regular re-evaluation of older drugs is necessary.